News Channels

15 Jan 2021 Dompé Announces First Patient Enrolled in Phase 3 trial of Ladarixin, an Oral Investigational CXCR1/2 Inhibitor, in New-Onset Type 1 Diabetes (T1D)
15 Jan 2021 Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing Cholangitis
15 Jan 2021 Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults
15 Jan 2021 Imfinzi approved in the EU for less-frequent, fixed-dose use in unresectable non-small cell lung cancer
15 Jan 2021 Ubiquigent and the University of York Awarded a Grant to Explore the Potential of Deubiquitylase (DUB) Enzyme Inhibitors to Address Neglected Tropical Diseases
15 Jan 2021 Syntekabio Signs Joint Development Agreement with Hanmi Science
14 Jan 2021 Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
14 Jan 2021 Vor Announces FDA Clearance of IND Application for VOR33
14 Jan 2021 Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19
13 Jan 2021 Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid Tumors
13 Jan 2021 Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors
13 Jan 2021 Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics
13 Jan 2021 AuraVax Therapeutics Enters into Exclusive License Agreement with Massachusetts General Hospital for Intranasal Vaccine and Therapeutics Platform
13 Jan 2021 EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen
13 Jan 2021 Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies
13 Jan 2021 Adastra Pharmaceuticals Announces Positive Top-Line Data from Phase 1b Clinical Trial of Zotiraciclib in the Treatment of Recurrent High-grade Gliomas
13 Jan 2021 LEO Pharma initiates head-to-head study to evaluate brodalumab vs. guselkumab in adult patients with moderate-to-severe psoriasis who have inadequate response to ustekinumab
13 Jan 2021 Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59
13 Jan 2021 KSQ Therapeutics and Takeda Enter Broad Strategic Collaboration to Research, Develop and Commercialize Novel Immuno-Oncology Therapies
13 Jan 2021 UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up